BioSpace News Archive

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that data from a study highlighting the health economic benefits associated with KidneyIntelX™ testing in diabetic kidney disease populations (DKD) will be presented at the National Kidney Foundation Spring Clinical Meeting.

KVK Tech, Inc. a U.S. manufacturer of high-quality generic pharmaceuticals, today issued $1,000 checks to all employees to support families during the disruption created by various local national, state, and local measures instituted to prevent the spread of COVID-19. “Over the last several weeks, everyone across the U.S. has h

China-based biotechnology company signs third agreement with pharmaceutical company gaining exclusive global rights to develop and commercialize anti-PD-L1 Antibody

Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in metastatic pancreatic cancer treatment-naïve patients MINNEAPOLIS, March 24, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic cancer, today provides a bu

Tabula Rasa HealthCare®, Inc., a healthcare technology company advancing the field of medication safety, is coordinating an effort to help Programs of All-Inclusive Care for the Elderly with access to COVID-19 testing kits.

New platform drives industry forward and opens up a new era for NGS technology

QIAGEN announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing patients infected with the novel COVID-19 coronavirus under a new Policy of the U.S. Food and Drug Administration announced on March 16. QIAGEN will submit this week the related Emergency Use Authorization to the FDA.

Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced the appointment of David Happel as Chief Executive Officer.

Novavax, Inc. announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older.

POINT Biopharma Inc. announced the appointment of Todd Hockemeyer as Executive Vice President of US Manufacturing Operations.